ONCAlert | Upfront Therapy for mRCC

Exploring Abemaciclib for the Treatment of Brain Metastases in HR+/HER2- Breast Cancer

Sara M. Tolaney, MD, MPH
Published Online: 7:00 PM, Tue June 6, 2017

Sara M. Tolaney, MD, MPH, associate director, clinical research, breast oncology, Susan F. Smith Center for Women’s Cancers, Dana-Farber Cancer Institute, discusses interim results of a trial exploring abemaciclib for the treatment of brain metastases secondary to hormone receptor-positive HER2-negative breast cancer.

Copyright © TargetedOnc 2020 Intellisphere, LLC. All Rights Reserved.